JP2014508784A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014508784A5 JP2014508784A5 JP2014500216A JP2014500216A JP2014508784A5 JP 2014508784 A5 JP2014508784 A5 JP 2014508784A5 JP 2014500216 A JP2014500216 A JP 2014500216A JP 2014500216 A JP2014500216 A JP 2014500216A JP 2014508784 A5 JP2014508784 A5 JP 2014508784A5
- Authority
- JP
- Japan
- Prior art keywords
- treatment
- radiolabeled compound
- cancer
- radioactive imaging
- breast cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 238000003384 imaging method Methods 0.000 claims 1
- 230000002285 radioactive effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161467764P | 2011-03-25 | 2011-03-25 | |
| US61/467,764 | 2011-03-25 | ||
| PCT/CA2012/000316 WO2012129673A1 (en) | 2011-03-25 | 2012-03-26 | INHIBITORS OF 17ß-HSD1, 17ß-HSD3 AND 17ß-HSD10 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017253315A Division JP6727184B2 (ja) | 2011-03-25 | 2017-12-28 | １７β−ＨＳＤ１、１７β−ＨＳＤ３、および１７β−ＨＳＤ１０の阻害剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014508784A JP2014508784A (ja) | 2014-04-10 |
| JP2014508784A5 true JP2014508784A5 (https=) | 2016-10-27 |
Family
ID=46929260
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014500216A Withdrawn JP2014508784A (ja) | 2011-03-25 | 2012-03-26 | １７β−ＨＳＤ１、１７β−ＨＳＤ３、および１７β−ＨＳＤ１０の阻害剤 |
| JP2017253315A Expired - Fee Related JP6727184B2 (ja) | 2011-03-25 | 2017-12-28 | １７β−ＨＳＤ１、１７β−ＨＳＤ３、および１７β−ＨＳＤ１０の阻害剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017253315A Expired - Fee Related JP6727184B2 (ja) | 2011-03-25 | 2017-12-28 | １７β−ＨＳＤ１、１７β−ＨＳＤ３、および１７β−ＨＳＤ１０の阻害剤 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US11072632B2 (https=) |
| EP (1) | EP2688901B1 (https=) |
| JP (2) | JP2014508784A (https=) |
| AU (1) | AU2012234682A1 (https=) |
| CA (1) | CA2830984C (https=) |
| WO (1) | WO2012129673A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201512215A (zh) * | 2013-06-25 | 2015-04-01 | Forendo Pharma Ltd | 治療活性雌三烯噻唑衍生物 |
| JP6456373B2 (ja) | 2013-06-25 | 2019-01-23 | フォレンド ファーマ リミテッド | １７β−ヒドロキシステロイドデヒドロゲナーゼ タイプ１の阻害剤として治療活性のあるエストラトリエンチアゾール誘導体 |
| WO2015169971A1 (en) * | 2014-05-09 | 2015-11-12 | Tangent Reprofiling Limited | Modulators of androgen synthesis |
| EP3194419B1 (en) * | 2014-09-11 | 2018-09-05 | Bayer Pharma Aktiengesellschaft | 3-nitrogen or sulphur substituted oestra-1,3,5(10),16-tetraene akr1c3 inhibitors |
| CZ307437B6 (cs) | 2016-06-07 | 2018-08-22 | Ăšstav organickĂ© chemie a biochemie AV ÄŚR, v.v.i. | 15β-substituované deriváty estronu jako selektivní inhibitory 17β-hydroxysteoiddehydrogenáz |
| HRP20240679T1 (hr) | 2017-06-08 | 2024-08-16 | Organon R&D Finland Ltd | 17-oksimi 15.beta.-[3-propanamido]-supstituiranih etera-1,3,5(10)-trien-17-ona za uporabu u inhibiciji 17.beta.-hidroksisteroid dehidrogenaza |
| WO2024020520A2 (en) * | 2022-07-20 | 2024-01-25 | Board Of Regents, The University Of Texas System | Enzyme compositions, steroid derivatives, enzyme inhibitors, and methods of making same for pharmaceutical applications |
| IL326489A (en) * | 2023-08-15 | 2026-04-01 | Univ Laval | 17 irreversible HSD1 inhibitors in the cell |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5232917A (en) * | 1987-08-25 | 1993-08-03 | University Of Southern California | Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series |
| DE3888269T2 (de) * | 1987-09-24 | 1994-07-07 | Jencap Research Ltd | Hormon-Zusammensetzung und -Anwendung. |
| IL112778A0 (en) * | 1994-03-04 | 1995-05-26 | Merck & Co Inc | Substituted heterocycles, their preparation and pharmaceutical compositions containing them |
| US5952319A (en) * | 1997-11-26 | 1999-09-14 | Research Triangle Institute | Androgenic steroid compounds and a method of making and using the same |
| US6933312B2 (en) * | 2002-10-07 | 2005-08-23 | Agouron Pharmaceuticals, Inc. | Pyrazole derivatives |
| TWI331154B (en) | 2003-11-12 | 2010-10-01 | Solvay Pharm Gmbh | Novel 17-hydroxysteroid dehydrogenase type i inhibitors |
| CN101189251B (zh) | 2005-05-26 | 2012-09-12 | 索尔瓦药物有限公司 | 17β-HSD1和STS抑制剂 |
| US10174070B2 (en) * | 2005-09-30 | 2019-01-08 | Endece Llc | 6-substituted estradiol derivatives and methods of use |
| MX2009002579A (es) * | 2006-09-19 | 2009-03-20 | Solvay Pharm Gmbh | Derivados de estratrieno y sus usos como inhibidores de 17beta-hidroxiesteroide deshidrogenasa. |
| AU2007327653B2 (en) | 2006-11-30 | 2013-04-18 | Solvay Pharmaceuticals Gmbh | Substituted estratrien derivatives as 17beta HSD inhibitors |
| US20080171728A1 (en) | 2007-01-12 | 2008-07-17 | Quatrx Pharmaceuticals Co. | Efficient Process for Preparing Steroids and Vitamin D Derivatives With the Unnatural Configuration at C20 (20 Alpha-Methyl) from Pregnenolone |
| EP2014672A1 (en) * | 2007-07-12 | 2009-01-14 | Bayer Schering Pharma Aktiengesellschaft | 8-beta-substituted estratrienes as selectively active estrogens |
-
2012
- 2012-03-26 US US14/007,577 patent/US11072632B2/en not_active Expired - Fee Related
- 2012-03-26 EP EP12765822.7A patent/EP2688901B1/en active Active
- 2012-03-26 JP JP2014500216A patent/JP2014508784A/ja not_active Withdrawn
- 2012-03-26 CA CA2830984A patent/CA2830984C/en active Active
- 2012-03-26 AU AU2012234682A patent/AU2012234682A1/en not_active Abandoned
- 2012-03-26 WO PCT/CA2012/000316 patent/WO2012129673A1/en not_active Ceased
-
2017
- 2017-12-28 JP JP2017253315A patent/JP6727184B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL3725810T3 (pl) | Terapia skojarzona obejmująca przeciwciała przeciwko Klaudynie 18.2 do leczenia nowotworu złośliwego | |
| HUS1900007I1 (hu) | Kiméra, antigénreceptor-módosított T-sejt alkalmazása rák kezelésére | |
| JP2014508784A5 (https=) | ||
| LT2847225T (lt) | Antikūnai prieš klaudiną 18.2 tinkami vėžio diagnozavimui | |
| PL2958945T3 (pl) | Terapia skojarzona wykorzystująca przeciwciała przeciwko klaudynie 18.2 do leczenia nowotworu | |
| ZA201603380B (en) | Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer | |
| IL235607A0 (en) | Combination therapy involving antibodies against claudin 18.2 for treatment of cancer | |
| PT2976360T (pt) | Terapia envolvendo anticorpos contra claudina 18.2 para o tratamento de cancro | |
| LT3319993T (lt) | Axl specifiniai antikūno-vaistokonjugatai, skirti vėžiui gydyti | |
| EA201400178A1 (ru) | Лечение рака молочной железы | |
| HUE043463T2 (hu) | Vírusszerû részecske konjugátumok tumorok kezelésére | |
| HUE047198T2 (hu) | Fitokannabinoidok emlõrák kezelésére | |
| PT4095130T (pt) | Inibidores marcados do antígeno de membrana específico da próstata (psma), seu uso como agentes de imagem e agentes farmacêuticos para o tratamento do cancro da próstata | |
| ZA201706402B (en) | C.novyi for the treatment of solid tumors in humans | |
| HRP20180670T1 (hr) | Novi postupak dobivanja spojeva namijenjenih upotrebi u liječenju raka | |
| PT3053578T (pt) | Terapêutica de combinação de cancro usando composto de azabiciclo | |
| SG11201509351UA (en) | Novel compounds for the treatment of cancer | |
| IL245551A0 (en) | Anti-matriptase antibodies for cancer treatment | |
| DK2802351T3 (da) | Midler til behandling af triple-negativ brystkræft | |
| LT2984108T (lt) | Anti-s100a7 antikūnai, skirti vėžio gydymui ir diagnozei | |
| SG11201506407VA (en) | Kit for tumor imaging | |
| IL237976A0 (en) | A derivative of 7-azaindole-2,7-naphthyridine for the treatment of tumors | |
| IL245477A0 (en) | Diagnosis of lung cancer | |
| PT3643707T (pt) | Composto marcado com 18f para o diagnóstico do cancro da próstata e a respetiva utilização | |
| AP2015008905A0 (en) | Novel compounds for the treatment of cancer |